Get the Stockscreener App
249.33
0.26%
-0.66
After Hours:
250.34
1.01
+0.41%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $249.33, with a volume of 603.63K.
It is down -0.26% in the last 24 hours and down -2.63% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$249.99
Open:
$250.98
24h Volume:
603.63K
Relative Volume:
0.63
Market Cap:
$36.84B
Revenue:
$4.81B
Net Income/Loss:
$1.11B
P/E Ratio:
40.48
EPS:
6.16
Net Cash Flow:
$1.35B
1W Performance:
+3.22%
1M Performance:
-2.63%
6M Performance:
+16.91%
1Y Performance:
+63.42%
1-Day Range:
$247.91
$251.36
1-Week Range:
$240.69
$251.36
52-Week Range:
$151.95
$260.49
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
249.33 | 36.84B | 4.81B | 1.11B | 1.35B | 6.16 |
|
ISRG
Intuitive Surgical Inc
|
538.55 | 192.83B | 7.87B | 2.24B | 586.00M | 4.25 |
|
BDX
Becton Dickinson Co
|
221.98 | 64.77B | 20.18B | 1.73B | 3.07B | 5.51 |
|
ALC
Alcon Inc
|
88.23 | 43.75B | 9.76B | 1.16B | 665.00M | 0.72 |
|
WST
West Pharmaceutical Services Inc
|
323.32 | 23.33B | 2.88B | 499.60M | 321.60M | 7.41 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed CEO’s Stock Transactions and Options Activity - TipRanks
ResMed CEO Michael Farrell sells $499k in stock - Investing.com
Home Healthcare Software Market to Surpass USD 38.92 Billion by 2032 at a CAGR of 13.8% - GlobeNewswire Inc.
Qsemble Capital Management LP Makes New $728,000 Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
Daiwa Securities Group Inc. Increases Stock Position in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc’s Peter Farrell Alters Stock Holdings - TipRanks
ResMed Inc. stock rises Tuesday, still underperforms market - MarketWatch
Downgrading ResMed Inc. Because It's Doing Well (NYSE:RMD) - Seeking Alpha
Dynamic Technology Lab Private Ltd Purchases 7,165 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
Zacks.com featured highlights include InterDigital, Greenbrier, Leidos, ResMed and Kontoor - Yahoo Finance
ResMed Inc Awards RSUs to Director Desney Tan - MSN
ResMed Inc Plans Sale of Common Shares on NYSE - MSN
ResMed Inc Officer Sells Shares Amidst Market Attention - TipRanks
ResMed Director Acquires Shares, Signals Confidence - MSN
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed: Solid Execution, Pricey Valuation (NYSE:RMD) - Seeking Alpha
Insider Sell: Justin Leong Sells 6,160 Shares of ResMed Inc (RMD) - GuruFocus.com
ResMed chief product officer Justin Leong sells $1.5 million in stock - Investing.com
ResMed Stock: Is Wall Street Bullish or Bearish? - MSN
ResMed Inc’s Insider Stock Acquisition by Chairman Emeritus - MSN
ResMed Stock: Is Wall Street Bullish Or Bearish? - Barchart
Investing in ResMed (NYSE:RMD) five years ago would have delivered you a 71% gain - Simply Wall St
ResMed Inc Director Expands Stock Holdings - MSN
ResMed Inc’s Director Acquires New Stock Holdings - MSN
Why is everyone talking about ResMed shares? - MSN
ResMed Inc Director Acquires Shares Through RSUs - TipRanks
Pacer Advisors Inc. Boosts Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stock Position in ResMed Inc. (NYSE:RMD) - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Grows Position in ResMed Inc. (NYSE:RMD) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Increases Position in ResMed Inc. (NYSE:RMD) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Buys Shares of 7,025 ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. stock rises Friday, still underperforms market - MarketWatch
Here's Why You Should Add RMD Stock to Your Portfolio Now - MSN
RSMDF (ResMed) Inventory-to-Revenue : 0.71 (As of Sep. 2024) - GuruFocus.com
RSMDF (ResMed) 5-Year Dividend Growth Rate : 5.10% (As of Sep. 2024) - GuruFocus.com
ResMed Shareholders Elect Directors, Ratify Accounting Firm - Investing.com
ResMed Inc. (RMD) Announces Key Decisions from Annual Stockholders Meeting - GuruFocus.com
ResMed Inc. Reinforces Commitment to Investors - TipRanks
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
Landscape Capital Management L.L.C. Purchases 7,128 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
Resmed Inc Announces Upcoming Stock Sale - MSN
ResMed Inc. Officer Plans Major Stock Sale - MSN
Caprock Group LLC Acquires 2,806 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. (NYSE:RMD) Shares Acquired by Natixis Advisors LLC - MarketBeat
Empowered Funds LLC Has $2 Million Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year - MSN
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD) - Yahoo Finance
Retireful LLC Makes New $742,000 Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
Meeder Asset Management Inc. Buys 3,174 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
Brokerages Set ResMed Inc. (NYSE:RMD) Price Target at $225.70 - MarketBeat
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):